Kimya & İlaç

Total Market Cap 1,440.4B
P/E (Weighted)Price to Earnings ratio. 38.66 Medyan: 20.66
P/B (Weighted)Price to Book ratio. 4.28 Medyan: 2.65
P/E (Arithmetic)Simple average P/E. 34.55
Avg Lothien ScoreFinancial health score (0-100). 57
Avg DamodaranDamodaran scoring model. 36
Avg PotentialExpected upside potential %. +13.7%
Avg Dalio ScoreDalio debt cycle score. 71
Distributions
Lothien Distribution
0–25
2
25–40
7
40–55
3
55–70
12
70–100
9
Damodaran Distribution
0–25
7
25–40
11
40–55
11
55–70
4
70–100
0
Upside Potential
-100% – -20%
11
-20% – +0%
4
+0% – +20%
5
+20% – +50%
5
+50%+
8

Data date 2026-10-16 Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Data date 2026-10-16
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Stocks in Sector
Stock PriceCurrent trading price. Market CapTotal market capitalization. FKPrice to Earnings ratio. PD/DDPrice to Book ratio. EV/EBITDAEnterprise Value / EBITDA. ROICReturn on Invested Capital. WACCWeighted Average Cost of Capital (WACC). PUSLAFinancial health score (0-100). DamodaranValuation score. Intrinsic ValueFair value via DCF model. Potential %Expected upside potential %. Dalio RiskDalio Debt Cycle Score Debt/EquityDebt to Equity ratio.
1419
65.30 19.5B 4.70 0.86 4.46 2.0% 10.9% 82 42 159.98 +104.4% 81 0.12
2915
58.90 62.9B 4.23 0.38 4.46 0.1% 10.4% 82 50 176.70 +148.0% 72 0.06
9907
15.00 23.7B 19.18 1.13 4.61 6.5% 9.7% 78 58 35.72 +103.6% 82 0.29
1904
25.60 28.4B 11.82 0.93 6.70 3.9% 6.6% 77 43 63.90 +95.7% 51 1.06
4766
361.00 43.5B 15.40 3.07 8.17 24.0% 10.4% 77 62 497.28 +28.3% 88 0.47
4763
46.50 46.0B 11.14 2.35 6.95 36.6% 11.8% 75 63 71.96 +41.1% 100 0.00
9939
128.50 38.0B 11.69 1.92 8.11 8.9% 7.7% 73 48 216.68 +49.4% 57 1.19
1907
29.55 49.1B 17.37 0.54 9.89 -0.2% 6.1% 72 43 54.37 +53.7% 45 0.66
1210
51.80 43.3B 12.73 1.70 6.90 6.4% 7.6% 71 51 91.40 +57.3% 57 1.14
1229
41.40 75.5B 16.95 1.20 13.95 1.4% 9.5% 70 45 67.23 +46.8% 72 0.19
1232
156.50 25.0B 16.47 4.54 10.44 39.1% 11.2% 69 56 163.72 +3.5% 95 0.27
1434
20.10 33.8B 20.76 0.69 14.43 1.2% 9.4% 67 28 28.14 +28.8% 64 0.23
1785
100.00 59.6B 14.95 3.67 11.34 15.6% 9.7% 64 45 113.26 +9.5% 70 0.94
1409
25.50 40.8B 18.95 0.98 13.57 3.7% 6.2% 64 48 46.49 +52.7% 36 1.63
1215
106.50 31.4B 12.27 2.87 10.78 9.2% 7.9% 62 35 126.73 +12.7% 52 1.70
1314
8.85 33.5B — 0.44 — -2.0% 6.4% 61 40 26.55 +86.0% 49 0.49
4770
273.00 21.8B 26.04 2.60 15.88 12.4% 11.7% 60 40 256.03 -4.5% 98 0.01
1440
14.10 23.4B 100.00 0.82 20.12 -1.3% 9.0% 57 30 17.63 +14.7% 46 0.36
1722
42.10 41.3B 50.27 0.78 16.13 0.8% 11.4% 57 26 50.20 +13.9% 77 0.04
1723
86.50 20.1B 25.10 2.51 16.18 6.4% 10.6% 56 29 75.23 -9.4% 77 0.32
1773
169.50 50.9B 20.56 4.45 14.62 15.8% 11.2% 56 37 138.44 -13.2% 78 0.26
1717
71.80 85.0B 38.16 2.73 16.54 3.9% 8.7% 48 29 56.87 -15.0% 66 0.78
5234
289.00 29.7B 34.49 8.95 23.45 22.4% 11.6% 46 39 149.98 -36.1% 88 0.11
5340
90.70 17.7B 49.81 7.45 29.56 15.4% 11.8% 42 30 38.65 -43.0% 97 0.01
7768
286.50 20.1B 61.43 4.48 32.99 7.0% 10.9% 40 24 130.33 -40.9% 89 0.37
1711
43.10 23.6B 100.00 2.65 33.75 -0.4% 10.6% 39 26 24.93 -27.0% 62 0.37
1560
903.00 135.7B 70.72 14.90 47.00 15.8% 10.6% 39 26 258.53 -53.5% 94 0.23
4749
724.00 68.3B 57.12 6.60 39.56 8.8% 10.5% 38 24 277.61 -46.2% 93 0.23
1802
62.70 182.3B 72.73 3.53 25.25 4.1% 9.7% 37 23 32.82 -34.3% 60 0.51
4764
183.00 16.8B 63.10 6.56 32.16 6.5% 10.5% 36 24 75.48 -44.1% 67 0.90
4722
202.50 21.0B 74.77 6.07 52.78 3.0% 10.3% 30 21 69.32 -47.4% 60 1.22
7887
148.00 12.1B — 28.90 — -24.9% 13.1% 25 0 37.00 -36.0% 81 0.44
4768
345.00 16.6B — 11.70 127.86 0.1% 10.7% 24 15 86.65 -47.9% 48 1.29

The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.